SCHEMBL5649255

SCHEMBL5649255

CCN(CC)CCCNC(=O)c1ccc(-c2nc3cc(Cl)c(Cl)cc3[nH]2)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS12 P56730 4/20 0.50
HTT P42858 2/20 0.49
TP53 P04637 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
GAA P10253 2/20 0.45
RHEB Q15382 1/20 0.44
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GLA P06280 1/20 0.43
HSD17B10 Q99714 1/20 0.43
USP7 Q93009 2/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
NSD2 O96028 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
PDE2A O00408 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
PRMT5 O14744 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651653 0.95 HTT (0.49) PRSS12HTTTP53SMN1; SMN2GAA
SCHEMBL5651662 0.95 HTT (0.49) PRSS12HTTTP53SMN1; SMN2GAA
SCHEMBL5648694 0.93 TP53 (0.47) PRSS12HTTTP53SMN1; SMN2GAA
SCHEMBL5648685 0.93 TP53 (0.47) PRSS12HTTTP53SMN1; SMN2GAA
SCHEMBL5648813 0.90 PRSS12 (0.49) PRSS12HTTTP53SMN1; SMN2GAA
SCHEMBL5653615 0.89 HDAC6 (0.46) HTTTP53SMN1; SMN2GAATSHR
SCHEMBL5650247 0.88 PRSS12 (0.50) PRSS12HTTTP53SMN1; SMN2GAA
SCHEMBL5653269 0.88 TP53 (0.47) PRSS12HTTTP53SMN1; SMN2GAA
SCHEMBL5651973 0.88 HTT (0.47) PRSS12HTTTP53SMN1; SMN2GAA
SCHEMBL5649708 0.88 PRSS12 (0.47) PRSS12HTTTP53SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 PRSS12 979/4885HTT 4354/4885TP53 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.